Plaque-Reduction Neutralization Assay

Serum samples were assayed for West Nile virus (WNV)–specific antibodies by using the plaque-reduction neutralization test as previously described (1). Briefly, each serum sample was diluted 1:5 in BA1 and mixed with an equal volume of BA1 containing a suspension of WNV NY99-4132 at a concentration of approximately 200 PFU/0.1 mL, such that the final serum dilution was 1:10 and the final concentration of WNV was approximately 100 PFU/0.1 mL. For the postinoculation serum samples, we also tested serial twofold dilutions of serum to determine endpoint 90%-neutralization titers. In most cases, preinoculation serum samples were tested for neutralizing antibodies to St. Louis encephalitis virus, a closely related flavivirus that may cross-react serologically with WNV (2) and may partially protect against WNV infection (3). After 1 h incubation at 37°C, 5% CO₂, virus-serum mixtures were assayed for virus content by plaque assay (see above). Controls used included BA1 only (cell viability control), bird serum-free virus mixture with BA1 only (to enumerate the number of PFU in the challenge dose of virus), and WNV hyperimmune mouse ascitic fluid (diluted 1:200) mixture with virus (positive control, to verify challenge virus identity).

Appendix A References